pharmaceut expand larg cap pharma
top larg cap idea myl/pcrx top smid top theme
launch coverag larg cap pharma op-rat top idea look
broad therapeut footprint three sector larg cap pharma ii specialti pharma iii
gener exhibit span divers stock rang small mega cap across growth
valu equiti cross-asset focu
larg cap pharma launch coverag op sp sp remain sp
come away follow recent hq visit bias posit larg cap pharma cogniz
host put take drill report elect year bring uncertainti
recent survey suggest sentiment low sector better own take bottom-up
approach stock select favor limit near-term loss exclus loe risk pipelin innov
balanc capit deploy structur margin expans stori
op price target like best-in-class growth newli shrunk biopharma base post
consumer/upjohn strateg action set inflect best growth revenu ep
limit loe ii see upsid vyndaqel ibranc two core
driver potenti revis iii balanc sheet under-lev robust dividend year
deploy capit bolster pipelin disprov bear case surround loe risk
initi set inflect cleaner high growth base initi op price target
sp price target robust growth stori well understood leav us bias favor
lack enough upsid bullish call keytruda strength remain primari driver
top-lin oper leverag revis trend like slow ii clear margin stori think
fulli bake street forecast iii bear case call valuat impair keytruda loe
risk think earli also fail see compel bull case sotp upsid
initi solid growth stori also healthi appreci initi sp price target
sp price target near-term cautiou follow run sinc mid-aug await next
strateg move fulli address humira loe mix deal
acknowledg manag potenti unlock valu prior manag via
break-up/divestitur ii street ep concern around greater margin pressur
street model iii valuat dividend add support initi report
cautiou margin outlook dividend larg initi sp price target
gener pharma outlook unchang prolong turnaround continu top idea
sector remain stuck turnaround hold pattern leverag concern persist ebitda
base continu see growth headwind unknown litig cash call opioid price fix
keep generalist investor sidelin fundament view detail report gener
pharma primer new environ unchang
op price target rais target link upjohn deal close set remov overhang
anticip sharehold turnov updat guidanc clear way better appreci newco
dividend yield leverag head modest ev/ebitda
specialti pharma stock select key meaning valu exist favor
coverag span broad market cap rang take bottom approach stock
select environ becom challeng ampl support right
product and/or manag team deliv meaning valu sever attract name
top idea target favor near-term set-up
price prior trade day market close estimate unless otherwis note
valu usd unless otherwis note
tabl content
pharmaceut expand larg cap pharma
coverag footprint broaden includ larg cap pharma specialti
outperform price target top idea larg cap pharma
sector perform price target favor bia upsid
sector perform price target cautiou given recent strength
stand top theme focu elect
theme loe debat includ address focu
theme major theme posit smid biotech tailwind
theme street bullish margin expans face price headwind
theme elect year drug price see meaning action unlik
theme china wildcard portfolio posit region matter
theme mean growth need drill stock
theme leav pocket inexpens growth versu broader market
theme sentiment gener neg add support angl
theme look meaning sector cross-read top one watch
theme surpris sever thing watch
appendix rais price target reflect deal link equiti
pharmaceut expand larg cap pharma
coverag footprint broaden includ larg cap pharma specialti
initi coverag larg cap pharma ad merck
exist footprint view three sector larg cap pharma specialti pharma
gener pharma exhibit detail current coverag span compani
small mega cap total billion market cap
exhibit break coverag footprint three distinct subsector larg cap pharma specialti pharma gener
larg cap pharmatickermarket cap enterpris valu ratingpricepric bia keytruda growth engin ii solid margin stori iii consensu long still work lc idea best growth lc ii under-lev balanc sheet upper end dividend iii address hurdl agn deal solv ii flat top-lin margin concern iii await next acquir assum deal close current narrow spreadspecialti pharmatickermarket capenterpris valu ratingpricepric targetcommentjazz catalyst heavi xyrem life-cycl clear ii asparaginas updat could surpris iii sunosi upsid revisit need csca growth pick ii rx tax overhang remain iii bolt-on deal sp idea expect favor guid set-up ii solid exparel growth iii approv lift overhang key fulvestr key driver data apr ii recent pemfexi deal add support iii cash focu recent growth encourag ii cash runway improv iii season ramp posit momentum recent quarter launch ii label updat add tailwind iii ampl move forward recent sti posit ii amphora pdufa iii cash runway key driver pdufa ii recent kol feedback encourag iii recent rais boost cash runway launch focu post approv ii hypopen approv catalyst iii eu approv twirla pdufa expect approv ii littl price stock iii cash runway option littl valu stock ii immin nda file iii debt restructur add runway pharmatickermarket capenterpris valu ratingpricepric gx idea upjohn deal close remov overhang ii newco dividiend yield robust iii valuat sidelin street out-year estim high ii growth strategi still unclear iii stock link stori execut risk still high ii pipelin offer upsid low visibl iii leverag still opioid headlin continu deliv ii opioid exposur wildcard iii leverag limit focu litig need address refin debt ii ebitda ramp encourag iii visibl still low pharmaceut expand larg cap pharma
outperform price target top idea larg cap pharma
like best class revenu ep growth group averag valuat
follow strateg move separ consum upjohn busi remain
lean busi come robust growth meaning oper leverag
sentiment name notabl low follow ep step-down well-
understood under-lev balanc sheet
healthi deal appetit mid stage pipelin asset five year introduc next wave
growth driver compani tactic begin deploy capit think valuat
follow potenti improv sector-high ep compound-annual-growth-rate
full report set inflect cleaner high growth base initi op price
exhibit forecast versu street street forecast notabl mix includ upjohn despit separ
 set inflect best class growth limit loe risk like
strateg move send
joint ventur
glaxosmithklin form newco combin upjohn busi
two move leav leaner faster grow despit ep step-down
deliv revenu compound-annual-growth-rate realist expect drive
ep compound-annual-growth-rate back one sector best margin stori given mix shift
higher margin product notabl oper leverag
consum busi
core product compris roughli half busi collect grow
growth led vyndaqel ibranc respect
street see potenti upsid biggest
mover like come ibranc back anticip palla trial
street model reflect continu growth think favor updat would
push forecast higher rel low risk data pipelin remain
swing factor sever product add growth
risk adjust model
biggest debat like remain around compani abil grow
time-frame would say two thing first sentiment around
name low think primarili reflect concern second under-
lever balanc sheet focu acquir mid-stag pipelin target five
year see busi develop activ pick think sentiment potenti
improv meaning pipelin support said differ per analysi pfizer
would need gener billion revenu support back-fil
order maintain robust growth time period would need find
billion new revenu sourc
includ upjohn mid mix difficult post-upjohn base pharmaceut expand larg cap pharma
balanc sheet offer meaning firepow deal think under-
appreci pfizer net lever end reflect receipt
billion proce upon close upjohn deal leav billion
cash flow capital-expenditure dividend deploy
includ potenti monet consum busi partner
glaxosmithklin publicli messag happen insid potenti
ad anoth billion billion pre-tax proce word see
meaning option smaller faster grow base allow grow
post
sector perform price target favor bia upsid
merck share continu move steadili higher back continu keytruda-
driven upward revis expect keytruda remain backbon merck
growth stori back host upcom data read ahead becom
compel margin expans stori said understood potenti
upsid surpris limit view forecast meaning differ
consensu overal street sentiment overwhelmingli posit leav stock
consensu long bucket overal bia share favor room upsid
initi sector perform rate full report solid growth
stori also healthi appreci initi sp price target
exhibit forecast versu street model revenu ep cagr million except per share
expect keytruda steadi driver growth better appreci
keytruda repres revenu rise underscor
import product growth driver product grow
compound-annual-growth-rate growth driven continu penetr non-small-cel lung
cancer nsclc still room penetr non-squam
nsclc squamou popul
monotherapi patient alk/egfr mutat
also signific opportun adjuvant/neoadjuv set
better understood data read next sever year npv work
keytruda per share major realiz ahead loss
solid oper margin stori one well understood core part stori
oper margin begin lift meaning beyond
manag point year invest though like look keep
expect strength keytruda-driven top line come
oper leverag seen sg compani shift spend away
legaci primari care asset keytruda program begin run
overal merck oper margin move
basi point higher put us basi point street drive
key driver street driven compound-annual-growth-rate modestli driven sg street annual pharmaceut expand larg cap pharma
ep delta level upsid potenti via margin import watch
bull case call sotp upsid unlock valu via divestitur struggl
see forecast big part bull case relat sotp upsid merck
diversifi footprint sever valu driver think sotp upsid
debat keytruda anim health keytruda npv get us per
share realiz end still healthi tail contribut
loe signific investor sell-sid focu unlock valu
divest anim health debat around compar valuat asid comp rang
enterpris valu take midpoint get valu
divest busi may ultim right move unclear much valu
unlock
bear case point keytruda loe risk risk valuat impair
see yet think earli merck under-levered balanc sheet
rel attract pipelin long lead time address loe hit close
busi januvia/janumet introduc loe model
merck grow look major competitor detail
experienc loe-rel overhang celgen
case stock began see pressur roughli year even keytruda consid
extrem still see lot time ahead address merck clear
feel need pursu major new ceo announc expect
question like linger
sector perform price target cautiou given recent strength
abbvi peer-best dividend yield valuat enough off-set concern
mix feel around pend allergan acquisit compani
address humira loss exclus acquir allergan continu see
growth headwind pro-forma revenu ep larg flat next year
allow ampl support de-lev grow dividend enough
view drive much need valuat re-rat said see opportun
strateg move via divestitur addit deal could help reposit
compani growth anticip pressur humira biosimilar
full report cautiou margin outlook dividend larg initi sp price
exhibit forecast versu street modestli street stand-alone basi exclud million except
see greater downsid humira biosimilar risk consensu expect concern
remain focu model per share npv pro-forma busi
estimatesrevenu compound-annual-growth-rate compound-annual-growth-rate pharmaceut expand larg cap pharma
current equiti valu debat die
somewhat particularli addit allergan still think swing
factor specif think street underestim initi step
humira see biosimilar enter
allergan acquisit partial answer humira mix
deal deal us seem financi engin given humira cliff
strateg bolster platform dont think would
done wasnt face humira loss exclus loe said
like medic aesthet busi even though doesnt add much strateg
allergan busi bring much need scale footprint
account allergan revenu base women could includ ad
anoth opportun divest acquir non-cor allergan asset
effect allergan fail break busi fact
believ could opportun spin medic aesthet busi well
time ultim drive meaning return transact
ultim manag board
key product compris revenu make
grow collect compound-annual-growth-rate street skyrizi rinvoq
orilissa botox line imbruvica venclexta abbvi legaci
overal immunolog hematolog franchis remain backbon
compani add medic aesthet follow allergan deal
core franchis compris revenu grow
ex-humira convinc remain busi declin per year
need core potenti divestitur could
boost growth given dilut natur
think street margin high big reason ep
forecast busi seen margin move lower ad billion
synergi equat basi point margin view enough off-set
declin side margin pressur like mount given combin
lower partnership profit grow contribut imbruvica
venclexta humira impact biosimilar also believ like
increas spend come year current revenu
pro-forma take billion plan cut allergan side well
larger biopharma peer closer
despit concern dividend yield valuat provid
support back anoth dividend increas announc novemb
yield add support level remain well ahead peer
commit grow go forward pro-forma price-to-earnings ep
near-term de-lev goal compani also lowest valuat among
peer think combin peer high dividend yield peer-low
pharmaceut expand larg cap pharma
stand top theme focu elect
exhibit base januari investor survey top theme earli year almost exclus target
smid cap biotech ii elect price neither surpris
themesector impactrbc viewcoverag exclus -stock impair loe need address earlier still need growth becom switch stori loe hit limit near-term risk expect busi develop focu high goal build pipelin grow biotech clear winneragrx top take-outstwo major theme potenti bid deal meaning gener target biopharma innov bolt-on deal back-fil major loe next year ie gener billion dividend oper leverag /-street model expans almost across board someth watch ie versu off-p ie differ compani sourc emerg ep qualiti discuss grow partnership price lever ad headwind work year drug pricing-w expect less investor concern around anyth meaning happen swing expect non-trump win repres sentiment riskthre thought sell-sid model buysid view reflect new net price growth norm expect anyth meaning get done point like move lower headlin go away could sentiment risk elect driver innov big risk older off-pat exposur /- -/ china repres big growth opportun one hard model limit exposur bigger debat concern expans vbp near-term risk long-term opportun less outlook focu bottom wide dispar compani sever name highli visibl robust growth outlook like debat whether better growth part healthcar less headlin risk fair offer select opportun inexpens growth rel market attractivepharma second inexpens sector market histor discount modestli wider could reflect elect risk sector out-siz base buysid survey could potenti better ownedour buysid survey point larg cap pharma sector one sector least upsid sell-sid buy rate lag healthcar peer per host updat come larg cap coverag impact stocksfocu major competit readssever event watch greatest focu like competit keytruda read poseidon surpris /-electionrepres downsid risk far left lean democrat take officelook focu ramp earli iowa caucu primari roll pharmaceut expand larg cap pharma
theme loe debat includ address focu
loss exclus normal part pharmaceut busi sever
larg upcom garner outsiz focu analysi show roughli
loe valuation/perform seen impact larger hole fill horizon
grow debat best address larg pipelin
exhibit base analysi notabl humira celgen revlimid
xyrem stock sell-off tend occur year ahead loe date
face next major loe humira lose us exclus
merck face major back half decad compani target smaller
deal drive innov pipelin counter rout acquir allergan
exhibit merck face major next year
pursu
acquisit
address humira loe
limit loe impact
pharmaceut expand larg cap pharma
theme major theme posit smid biotech tailwind
merck alon see billion capit next
dividend share repurchas deploy publicli
messag desir pursu smaller innov transact rais debt
capit balanc sheet arguabl under-lev add materi
tailwind smaller biotech therapeut landscap increas size
need build pipelin clearli investor focu open end
investor survey question last week around biggest theme next week major confer
call and/or area emerg biolog interest ie gene/cel therapi etc
exhibit see billion potenti deal capit
see billion
firepow
leverag use
brought larg scale deal expect merck focu smaller
bolt-on deal bristol/celgen abbvie/allergan among other shift investor focu
larg potenti transact merck publicli point smaller deal
exhibit merck commentari around
venuecommentjul ken frazier chairman earn call feel confid growth prospect go forward said past given interest particularli larg merger believ disrupt compani includ continu look bolt-on deal look across spectrum term size bolt-on divid dollar amount end day think oper complex cultur disrupt disrupt associ larg merger counsel go particularli feel confid abil grow compani organ supplement bolt-on deal dec chuck triano ir investor confer look deploy capit busi develop would mid-phas product target like product could launch mid-next decad product gener within five key therapeut area focus smaller deal someon ask us would anoth array billion brought us nice pipelin less like someth like probabl like see next coupl year make math easi say number million deal rather one billion deal think smaller in-licens mayb tuck-in pharmaceut expand larg cap pharma
theme street bullish margin expans face price headwind
margin expand
margin expans remain import theme across sector consensu forecast
notabl bullish next sever year major theme us within gener
reason cautiou view larg pharma lack structur
headwind sever thing think name price headwind chang
trend address product mix merck two biggest
near-term beneficiari margin expans see margin contract
driven us humira loss exclus
drug price fundament chang pharma price trend last
year well understood flat net price built corpor
buysid model point bigger risk see bipartisan deal come
washington would surpris low expect year ii elect
assum oper leverag someth increasingli focus
need back-fil drive growth beyond intern discoveri
deliv mean alloc greater free cash flow essenti
off-p spend ii earli stage deal get done come
greater need fund develop effect boost oper spend
shorter term invest cycl portfolio play
product mix given increas level collabor activ product mix weigh
margin partner product may overli obviou exampl growth
imbruvica venclexta posit weigh gross margin due
profit split
exhibit consensu model assum oper margin expans across board note
estim directli consist
rel street forecast
note show ibt margin instead oper margin
pharmaceut expand larg cap pharma
theme elect year drug price see meaning action unlik
expect bake
stock noth
price get done
consensu current reflect expect see signific bipartisan
drug price legisl suspect buysid exhaust dampen
headlin effect like see someth enact form
detail close follow propos exhibit propos
submit democrat republican trump administr also
vocal priorit issu throw support previous behind senat financ
committe prescript drug price reduct act pdpra recent
behind hr lower cost cure act said momentum lacklust
around mani propos administr actions/propos american
patient first blueprint lower drug cost price etc thu far
fairli limit outcom overal skeptic bake expect
anyth meaning get done year us bigger focu poll
momentum ultim elect result re-heat debat focu
exhibit summari main propos around drug price focus
proposalsimpactmain pointsmedicar part requir rebat paid compani price rise faster inflat medicar part cap out-of-pocket drug cost start provid discount brand drug initi phase part benefit discount spend catastroph threshold beneficari respons spend initi phase part benefit requir part sponsor pbm includ concessions/fe negoti price beneficiari pay counter incl rebat etc requir insur cap monthli out-of-pocket cost paid beneficiari given month spread multipl month prevent signific one-tim expens requir rebat paid compani price rise faster inflat miscellan pbm must report inform price concess payment pharmaci prescriptionsh elijah cum lower drug cost act part b/d/commerci medicar negoti least costli single-sourc drug per year appli discount privat health plan us penalti compani refus negoti gross sale drug agreement increas price exceed averag base refer countri averag manufactur price medicar part b/d penal compani rais price inflat lookback rate inflat lower price pay entir price inflat rebatemedicar part biosimilar encourag adoptionmedicar part pocket max start price modelmedicar part medicar set payment drug target price base discount given countri target price averag countri would pilot half countri initi physician would get set add-on payment independ price drug itselfsaf import action planmedicar part import certain drug canada version fda-approv drug excl biolog infus drug control substanc etc time propos rule draft guidanc publish draft guidanc releas manufactur fda-approv drug seek import us version drug sell foreign countri lower cost cure actmedicar part provid variabl percentag asp reimburs base rel cost lower beneficiari pocket spend discourag higher prescrib base reimburs add-on payment drug certain immunotherapi medicar part out-of-pocket cap elimin donut hole add manufactur respons miscellan requir manufactur notifi list price hike year yearstrump administrationtim pass hous dec senat decis next unlik support white hous also said trump veto billwaldentim unclear trump voic support billpelositim vote unclear senat major leader mcconnel support trump previous voic supportgrassley/wydenprescript drug price reduct act pdpra pharmaceut expand larg cap pharma
theme china wildcard portfolio posit region matter
meaning opportun
compani bring
innov drug
region risk older
sold
china repres opportun second-largest pharmaceut market
revenu evolv price environ reimburs dynam swing factor
volume-bas procur vbp implement march drug
provinc recent expand provinc initi drug next
wave ad drug roll-out expect april/may rule releas late
decemb procur offic guarante market share bid
winner next wave includ drug diabet cardiovascular infecti diseas
drug first wave contract word older off-
patent drug current market risk new reform difficult
navig seen pressur pfizer/upjohn lipitor norvasc
signific opportun look bring innov product
region compani point innov product drive futur growth
pivot off-pat product ie upjohn/mylan transact said even
innov drug compani typic forc make sizabl price concess
inclus nation reimburs drug list nrdl merck keytruda
includ nrdl compani note clear threshold
will make price/volum trade-off pfizer ibranc also includ due
price disagr point continu growth self-pay
market expect long-term growth need fuel nrdl inclus bottom
line region offer signific opportun come visibl challeng
exhibit china exposur rang broadli import growth market less swing factor
pharmaceut expand larg cap pharma
theme mean growth need drill stock
growth healthcar measur revenu ep slightli better
market averag whole sector trend remain favor per exhibit
outlook pharmaceut revenu ep growth near lowest within sector per
exhibit necessari drill intra-sector given broad rang among variou
pharmaceut compani ep compound-annual-growth-rate compar favor
healthcar broader market
exhibit revenu ep growth outlook constitu group gic sector
evolv busi model push innov platform drive wide rang
growth within sector look growth normal strateg
action close wide rang led pfizer ep compound-annual-growth-rate one end
abbvi flattish growth
exhibit revenu ep growth outlook healthcar constitu
compound-annual-growth-rate pharmaceut expand larg cap pharma
theme leav pocket inexpens growth versu broader market
pharmaceut sector measur drg exhibit histor trade
discount discount current widen put
sector close inexpens market next financi
exhibit pharma sector price-to-earnings discount rel current widen put second lowest ahead financi
note exclud real estat right chart
pharma valu growth leav room upsid
think add support re-rat compound-annual-growth-rate loe concern around
dissip confid grow sector growth current trade
exhibit larg cap pharma histor trade
price-to-earnings cap pharma pharma average pharmaceut expand larg cap pharma
theme sentiment gener neg add support angl
buysid feedback sell-sid rate suggest sentiment gener neg
poll investor subsector expect perform best similar question
septemb larg cap specialti pharma came near bottom
exhibit healthcar subsector expect perform best
buy sell-sid
base investor
survey look
percentag buy rate
look sell-sid buy rate among top healthcar compani market cap
yield similar messag except merck larg biopharma bottom four
exhibit top healthcar compani size buy equival sell-sid rate
ex-mco manag pharmaceut expand larg cap pharma
theme look meaning sector cross-read top one watch
exhibit import cross-read event come monitor
deriv companyderiv co productwhat watchcov companycov co productcommentsbeigenezanubrutinibsequoia phase interim data cll gen coval btk inhibitor competitor ibrutinib focu compar ae profil differencesastrazenecaacalabrutinibelevate-rr phase head-to-head studi result vs imbruvica gen coval btk inhibitor competitor ibrutinib current data compar focu compar ae profil differencesmyov sciencesrelugolixspirit phase endometriosi data spirit phase endometriosi data competitor orilissa endometriosi market shareneurocrin collabor orilissaphas data result uterin fibroid estim primari complet august neurocrin collabor opportun cross-read orilissa catalyst cover brian abraham obsevalinzagolixprimros phase uterin fibroid data competitor orilissa uterin fibroid opportun cover kennen mackaygalapago gileadfilgotinibfda approv ra eu ra approv select phase data uc rinvoq select inhibitor competitor xeljanz cover brian abraham astrazenecaimfinzi durvalumab nsclc poseidon phase updat os result nsclc market share bristol-my squibbopdivo nivolumab nsclc checkmat phase updat result nsclc market function readout develop pathway/lamb girdl timelin data competit direct competitor microdystrophin gene therapi program cover brian abraham solid dmd phase i/ii trial hold competitor dmd gene therapi program program clinic hold alnylamonpattro patisiran apollo trialvyndaqelttr protein silenc potenti vyndaqel competitor phase trial start sept target attr-cm indic current market polyneuropathyalnylamvutrisiranhelio trialsvyndaqelttr protein silenc potenti vyndaqel competitor helio enrol primari endpoint month phase studyvyndaqeldirect competitor tafamidi ttr stabilizereido trial attr-cmvyndaqeldirect competitor tafamadi ttr stabil expect fulli enrol phase top-lin data attr-cm month endpoint galapago gileadfilgotinibfda approv ra eu ra approv select phase data uc select inhibitor competitor xeljanz cover brian abraham pharmaceut expand larg cap pharma
theme surpris sever thing watch
would presum come hiccup regul concern close expect
spread current eu januari ftc updat soon
global opioid settlement posit gener depend term remain
biggest catalyst sever name includ teva endo one
continu think take time get done deal better term laid
framework link could help ralli sector lift largest overhang
increas rel keytruda neg bristol opdivo-
yervoy expect astrazeneca poseidon sometim
think loss nsclc market share unlik focu potenti
bristol opdivo yervoy chemotherapi combo astrazeneca
tremelimumab chemotherapi combo produc
improv
keytruda year overal surviv predictable/manag toxic profil
elect poll surpris neg healthcare/pharma novemb
event happen democrat primari poll also matter
focu far left candid poll could bring back concern healthcar
price reform senat sander warren poll low mid-teen
merck pivot pursu extern ceo chang strategi unclear see
unlik assum ceo transit announc come year includ
intern candid continu compani consist strateg
abrocitinib show meaning superior dupix phase posit
kol view regeneron dupix favor we/street heavili risk adjust
abrocitinib atop dermat underscor potenti surpris see meaning
superior dupix phase jade compar studi expect
decreas thromboembol risk profil jak inhibitor post-market studi
posit jak class pfizer xeljanz conduct phase post-market studi
expect primari complet date septemb follow-up data
lack statist signific relationship xeljanz
thromboembol event would posit surpris jak inhibitor class
humira interchang biosimilar neg could get updat
boehring ingelheim voltaire-x studi posit move
approv could drive eros expect lower biosimilar impact
though indic expect least one interchang biosimilar
pharmaceut expand larg cap pharma
appendix rais price target reflect deal link equiti
rais price target function chang market valu
abbv equiti acquir price target reflect abbv offer cash
share current trade price per share impli
ep estim stand-alone estim reflect single-digit ep growth forecast lack
meaning near-term catalyst drive upsid price target impli return support
sector perform rate continu expect deal close
capit market estim compani report
revenu revenu pharmaceut expand larg cap pharma
